Finance and operations veteran Rosemary Bensley is to lead the expansion of BR Pharma, a global clinical trial supply company that specialises in sourcing comparator drugs.
With revenue up 450% in two years, the company is keen to cultivate new business opportunities through Bensley's appointment.
"Rosemary brings a wealth of experience in accounting, finance, operations and consulting from a variety of industries," said Ben Rabin, chairman and founder of BR Pharma. "Our revenue has increased almost five-fold in the past two years, and we plan to enter new markets and expand existing business lines."
Leading sample management provider Titian Software has created a US subsidiary in Hopkinton, Massachusetts and appointed Michael Girardi as its president.
Girardi, who has previous senior management and leadership experience working for Tecan, has a track record of building sales and support operations in the life science sector. Girardi will be responsible for furthering Titian's north American customer relationships and product penetration into markets that the company serves.
Titian specialises in sample management software for the life science industry and its Mosaic software suite is already in use in six of the world's top 20 bio-pharma companies.
A highly experienced executive and entrepreneur joins the 4-Antibody Board, bringing with him expertise in antibody development and deal making. Professor Donald Drakeman, who joined as a venture partner at Advent Ventures earlier this year, co-founded two leading monoclonal antibody companies, Medarex and Genmab and has overseen the progress of numerous innovative new antibody therapeutics for cancer, infectious disease and inflammation from research concept to clinical trials.
A consulting firm providing outcomes research and health economics services to the global biopharmaceutical and healthcare industries, has added Anthony J. Vita and Peter Herout to its team of clinical professionals. The appointments will allow EPI-Q to support clients needing to enhance the clinical outcomes and cost-effectiveness of patient care. Herout has expertise in critical care and cardiology and Vita has clinical skills in mental health - a therapeutic category in which EPI-Q's business is rapidly expanding. They will be responsible for providing clinical support and managing projects.
Symetix's international sales manager, Subhash Mehta, will be bringing the company's product lines and high volume optical inspection and grading systems to the international pharmaceutical and nutraceutical industries through his new appointment.
With interest in such products as the Continuous Softgel Finishing Lines skyrocketing, Subhash is ideally suited to take the lead in expanding its international organisation according to company managing director Rich Hebel.
A biopharmaceutical company involved in the discovery and development of therapeutic molecules using the modulation of cell death has named Dr Olivier Chesnoy as chief executive officer and chairman of its board. Theraptosis" appointment of the 48 year-old will allow its co-founder, Etienne Jacotot, to focus fully on chief scientific officer activities.
Chesnoy, formerly of the Fournier pharmaceutical group, has extensive pharma industry experience, which comes at a time when the company is about to put its first product through clinical trials.
Dr Roger Lias's appointment to president of Eden Biodesign USA, is expected to prove pivotal in boosting the global strategy of the company. The company, which provides development and manufacturing services for new biopharmaceutical medicines, will benefit from Lias's experience in biomanufacturing services. His responsibilities will include identifying and establishing strategic business partnerships and expanding the company's offer to the large US biopharmaceutical sector. Lias joins Eden Biodesign from Cytovance Biologics.
Lock Inspection Systems has appointed Simon Taylor as marketing and sales manager. The appointment reflects Lock's determination to build on its position as technology leader in metal detection to grow and strengthen its market positions within the pharmaceutical industry.
Taylor has 20 years international marketing and sales experience industry, and will also take responsibility for UK and export sales.
Sir Walter Bodmer's broad ranging experience in genetics and biology and his current work in the field of colorectal cancer, is expected to make an important contribution to the Oxford Genome Sciences (OGeS) scientific advisory board - of which he has been recently appointed to. Bodmer heads the Cancer and Immunogenetics Laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford.
His laboratory will be collaborating on the evaluation of OGeS cancer drug development candidates in the area of colorectal cancer.
A former employee of Roche has been appointed vice president of clinical research and development at Synosia Therapeutics. Dr Uwe Meya will be based in the company's Swiss office in Basel.
Meya has spent more than 20 years in pharmaceu-tical research and development, focused on disor-ders of the central nervous system (CNS). His experience spans multiple CNS indications and covers the full spectrum of drug development from first- in-man through to regulatory filing.
"It's an exciting time to be joining Synosia with four compounds entering phase 2 studies in 2008 and another preparing to enter a proof-of-concept study," said Meya.